GSK gets Rainbow Tick. Promotion of rainbow diversity through a safe, inclusive environment needed in the workplace says Anna Stove.
These press releases are intended for business journalists and analysts/investors
The Unity Tool helps those with HIV optimise treatment by making patients feel more comfortable about disclosing their health needs.
Programs targeted at Maori and Pasifika cultures needed to reduce impact of severe asthma. Culture based treatment improves asthma outcome.
Breo Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Primary endpoint showed patients initiated with Breo Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care.
Experts say kiwis not managing their asthma. A recent report showed the incidence of asthma in NZ is among the highest in the world.
Diseases such as typhoid and dengue fever are possible risks for Fiji after Cyclone Winston. GSK has provided funding and various medicines to provide relief for Fiji.
A new funded device available for those who suffer from asthma and COPD. The Ellipta inhaler is easier to use therefore ensures the best outcome for patients.
Transparency is needed in the pharmaceutical industry. Engaging ethically with healthcare professionals increases patient assurance.
COPD rates are increasing at an impact, by 2030 it will be the third leading cause of death worldwide. Early diagnosis is the key to create a better quality of life.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. We help people around the world do more, feel better and live longer.